他汀类药物抵抗及其分子机制研究进展

Research progress on statins resistance and its molecular mechanisms

血脂异常是心血管病的主要危险因素,尤其是低密度脂蛋白胆固醇(LDLC)升高显著增加动脉粥样硬化性心血管疾病(ASCVD)发病率。他汀类药物已被证实可以有效降低血清LDLC,进而减少ASCVD发生风险。但是在他汀类药物的临床应用过程中,越来越多的研究显示他汀类药物存在耐药性,即药物抵抗。研究表明,他汀类药物抵抗主要受药物在体内的吸收、转运、代谢以及药物作用本身的影响。深入研究他汀类药物抵抗可为进一步揭示他汀类药物作用机制提供理论依据,并有望为研发新的降脂药物提供靶点。

Dyslipidemia is a major risk factor for cardiovascular disease, especially elevated low density lipoprotein cholesterol (LDLC) significantly increases the incidence of atherosclerotic cardiovascular disease (ASCVD). Statins have shown to be effective in reducing serum LDLC, thereby reducing the risk of ASCVD. However, in the course of clinical application of statins, more and more studies show that statins have drug resistance. Studies have shown that statin resistance is mainly affected by drug absorption, transport, metabolism and drug action itself. Intensive study of statin resistance can provide theoretical basis for further revealing the action mechanism of statins, and hopefully provide a target for the development of new lipid-lowering drugs.